Esperion Therapeutics Announces Two Oral Presentations for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Esperion Therapeutics Announces Two Oral Presentations for ETC-1002 at the American Heart Association Scientific Sessions 2015

ANN ARBOR, MI --(Marketwired - November 04, 2015) - Esperion Therapeutics, Inc. ( NASDAQ : ESPR ), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced Christie Ballantyne, MD, professor at Baylor College of Medicine and director of Houston Methodist DeBakey Heart and Vascular Center, will present full results from the Phase 2b ETC-1002-009 clinical study during the American Heart Association (AHA) Scientific Sessions 2015. The abstract, "ETC-1002 Incrementally Lowers Low Density Lipoprotein Cholesterol in Patients with Hypercholesterolemia Receiving Stable Statin Therapy," will be presented in an oral presentation on Monday, November 9, 2015 at 6:30 p.m. Eastern Time at the Orange County Convention Center, Orlando, FL in Room W205. Stephen Pinkosky, senior scientist and head of translational research at Esperion Therapeutics, will present the abstract, "Identification of a Tissue Specific Very Long Chain Acyl-CoA Synthetase Involved in the Inhibition of ATP-Citrate Lyase (ACL) by ETC-1002: A Novel Mechanism for Cholesterol Biosynthesis Inhibition in the Liver," in an oral presentation on Monday, November 9, 2015 at 11:45 a.m. Eastern Time in Room W303.

Conference Call and Webcast Information

Esperion will host a live webcast briefing on Tuesday, November 10, 2015 at 7:45 a.m. Eastern Time to provide full clinical results of the Phase 2b ETC-1002-009 study and new data on ATP Citrate Lyase inhibition, the mechanism of action for LDL-C lowering for ETC-1002. The webcast can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start and providing access code 68066683. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the Esperion website at www.esperion.com . A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the Company's website for 90 days following the event.

About ETC-1002-009

The 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group Phase 2b study evaluated the efficacy and safety of ETC-1002 versus placebo when added to low- and moderate-dose stable statin therapy in patients with hypercholesterolemia -- also known as the "add-on to statin" study. Secondary objectives were to characterize the dose response; assess the effect of ETC-1002 on additional lipid and cardiometabolic risk markers, including hsCRP; and characterize the safety and tolerability of ETC-1002. A total of 134 patients with hypercholesterolemia were washed out of any lipid-regulating therapies, except atorvastatin, simvastatin, rosuvastatin, or pravastatin. Forty-three* patients received ETC-1002 120 mg; 45 patients received ETC-1002 180 mg; 45 patients received placebo.

*One patient was randomized but did not receive study drug.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with hypercholesterolemia by developing therapies to lower LDL-C. Esperion scientists discovered ETC-1002 and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both ETC-1002 and a fixed dose combination of ETC-1002 and ezetimibe with a particular focus on patients with hypercholesterolemia who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia. ETC-1002 (bempedoic acid), the Company's lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. ETC-1002 inhibits cholesterol synthesis, decreases intracellular cholesterol, up-regulates LDL-receptors, and causes increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc .

Media Contact: Elliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 134

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 118

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Lyft Upgraded to Buy: Insights for Future Growth Potential

Updated Category News Views 292

Lyft's Upgrade by Benchmark: A Closer Look Benchmark analysts have recently upgraded Lyft (NASDAQ: LYFT) from Hold to Buy, highlighting what's described as "significant optionality" for the rideshare company. This decision comes despite the heightened competition from major players like Tesla and Waymo, indicating confidence in Lyft's capability to navigate potential...

Continue Reading
LiveOne Board Changes Amid Expansion and Financial Growth

Updated Category News Views 120

LiveOne Announces Departure of Board Member LiveOne, Inc. (NASDAQ:LVO) has recently made headlines in the retail-eating sector with the announcement of Craig Foster's resignation from its board of directors. Foster, who also contributed to the Audit Committee and Nominating and Corporate Governance Committee, stepped down to focus on his other professional commitments....

Continue Reading
Concorde International Group's Remarkable 80% After-Hours Surge

Updated Category News Views 429

Concorde International Group's Stock Surge Explained Concorde International Group Ltd. (NASDAQ: CIGL) has captured attention in the stock market after experiencing an impressive 80.16% increase during after-hours trading, reaching a price of $4.63. Investors are buzzing and speculating about what led to this dramatic leap. Exciting New Equity Incentive Plan Announced The...

Continue Reading
Celebrating the Legacy of Dr. Iain Douglas-Hamilton

Updated Category News Views 301

Special Screenings of A Life Among Elephants In a remarkable celebration of conservation, special screenings of the inspiring film A Life Among Elephants will honor the legacy of Dr. Iain Douglas-Hamilton. This film encapsulates the essence of his lifelong dedication to elephant conservation, portraying not only the threats faced by these majestic creatures but also the...

Continue Reading
Saudi Arabia Launches Major SME Report at Biban24 Event

Updated Category News Views 75

Saudi Arabia Presents Key Economic Insights at Biban24 As Saudi Arabia continues its path toward achieving ambitious Vision 2030 objectives, Monsha'at, the authority dedicated to small and medium enterprises (SMEs), is hosting Biban24. This significant event, designed to promote entrepreneurship and growth opportunities, brings together global entrepreneurs and investors...

Continue Reading